2015
DOI: 10.4155/ppa.15.1
|View full text |Cite
|
Sign up to set email alerts
|

Melanocortin-4 Receptor Modulators for the Treatment of Obesity: a Patent Analysis (2008–2014)

Abstract: The central melanocortin system and particularly the melanocortin-4 receptor (MC4R) subtype, plays an important role in the regulation of body weight. The discovery of orally active MC4R agonists suitable for evaluation in human clinical trials as weight loss agents has attracted considerable interest over the past decade, but has proved challenging, in part because of cardiovascular and behavioral side effects. Currently, the only MC4R agonist in clinical trials is a peptide identified as RM-493. To avoid som… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
10
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 45 publications
0
10
0
Order By: Relevance
“…Indeed, MC4R mutations represent the most prevalent form of monogenic obesity (0.5–6% of obese individuals) 52 , and MC4R variations are highly correlated with fat mass 128 . However, contrasting this pathological association is the potential of the MC4R as a pharmacotherapeutic target for obesity 129,130 . Consistent with rodent studies, pharmacological compounds that augment MC4R signaling promote appetite suppression and weight loss in humans 130 .…”
Section: Mc4r Pharmacotherapymentioning
confidence: 99%
See 2 more Smart Citations
“…Indeed, MC4R mutations represent the most prevalent form of monogenic obesity (0.5–6% of obese individuals) 52 , and MC4R variations are highly correlated with fat mass 128 . However, contrasting this pathological association is the potential of the MC4R as a pharmacotherapeutic target for obesity 129,130 . Consistent with rodent studies, pharmacological compounds that augment MC4R signaling promote appetite suppression and weight loss in humans 130 .…”
Section: Mc4r Pharmacotherapymentioning
confidence: 99%
“…Consistent with rodent studies, pharmacological compounds that augment MC4R signaling promote appetite suppression and weight loss in humans 130 . Unfortunately, these drugs influence other MC4R-regulated processes, such as cardiovascular tone, sexual function and pandiculation, limiting their clinical application 129 . At present only one MC4R compound, setmelanotide (RM-493; Rhythm Pharmaceuticals), is undergoing clinical trials, and only for use in the rare obesity conditions Prader-Willi syndrome and POMC deficiency.…”
Section: Mc4r Pharmacotherapymentioning
confidence: 99%
See 1 more Smart Citation
“…The development of MC4R-selective ligands for the treatment of common dietary obesity has so far not resulted in an approved drug, although the nonselective MC4R agonist setmelanotide is currently under priority review at the FDA for certain forms of syndromic obesity. 10,11 Despite intense research efforts in both academia and industry, there remains a need for potent, selective, and stable (ant)agonist ligands for the melanocortin receptors. So far, efforts have focused on variations of known ligands, but the structural requirements for designing receptor-selective ligands are still not straightforward to unravel.…”
Section: ■ Introductionmentioning
confidence: 99%
“…Currently, there are estimated to be more than 650 million adults with obesity worldwide (25). As obesity is related to different comorbidities such as diabetes mellitus type 2 or cardiovascular disease (26), there is considerable medical, pharmacological, as well as economic interest concerning this receptor (27). The design of highly selective and potent MC4R ligands (28, 29) should be a tool to counteract specifically against obesity (9, 30), which also needs a comprehensive understanding of this receptor under structural-functional perspectives.…”
Section: Introductionmentioning
confidence: 99%